---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-312912"
form_type: "8-K/A"
ticker: "DMRA"
cik: "0001800315"
company_name: "Damora Therapeutics, Inc."
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:48:57.286913+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.05
calibrated_materiality_score: 0.05
confidence: "high"
source: SEC EDGAR
---

# Galecto corrects Series C Preferred Stock authorization from 43,855 to 43,882 shares

## Summary
- Filed Certificate of Correction on Dec 5, 2025 to fix inadvertent error in Series C Preferred Stock designation.
- Authorized shares revised to 43,882 from incorrectly stated 43,855; no other terms changed.
- Amendment amends 8-K originally filed Nov 10, 2025; restated certificate attached as Exhibit 3.3.

## SEC filing metadata
- accession: 0001193125-25-312912
- form_type: 8-K/A
- ticker: DMRA
- cik: 0001800315
- company_name: Damora Therapeutics, Inc.
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.05
- calibrated_materiality_score: 0.05
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1800315/000119312525312912/0001193125-25-312912-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1800315/000119312525312912/glto-20251110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-312912
- JSON: https://secwatch.observer/filing/0001193125-25-312912.json
- Plain text: https://secwatch.observer/filing/0001193125-25-312912.txt

## Key facts
- Governance Changes
  Damora Therapeutics, Inc.: Corrected authorized shares of Series C Preferred Stock from 43,855 to 43,882 (effective 2025-12-05).
  - Change: charter amendment
  - Effective: 2025-12-05
  source text: On December 5, 2025, the Company filed with the Delaware Secretary of State a Certificate of Correction (the “Certificate of Correction”) to the Certificate of Designation of Series C Preferred Stock to correct an inadvertent error in the number of shares of Series C Non-Voting Convertible Preferred Stock, par value $0.00001 per share (the “Series C Preferred Stock”), that the Company is authorized to issue by modifying Section 2 of the Certificate of Designation of Series C Preferred Stock to correctly state that the number of authorized shares of Series C Preferred Stock is 43,882 shares instead of 43,855 shares.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1800315/000119312525312912/0001193125-25-312912-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.